Schumann MA, Gaasch A, Boyaci S, Fuchs F, Walter F, Marschner SN, Eze C, Westphalen CB, Holch JW, Beyer G, Kunz WG, Mayerle J, Niyazi M, Belka C, Corradini S, Rogowski P. Five-fraction stereotactic magnetic resonance-guided adaptive radiotherapy targeting the primary tumor in metastatic pancreatic cancer. World J Gastroenterol 2026; 32(29): 117832 [DOI: 10.3748/wjg.117832]
Andrzej S Tarnawski, MD, PhD, Professor
August 11, 2026, 09:07
The authors present a prospective observational study evaluating the feasibility, safety, and efficacy of 5-fraction stereotactic MRI-guided adaptive radiotherapy (MRgRT) for the primary tumor in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). The study addresses a clinically relevant topic. The use of MR-guided adaptation represents a state-of-the-art technical approach to this problem.
Please LOGIN to submit a new comment.